Skip to main
CRDL

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics is expected to be successful in their development of CardiolRx due to strong peer-reviewed Phase II data supporting its oral use, quick and lasting response in relieving recurring pericarditis pain, and potential for use as an oral steroid-sparing option. The company also has a strong financial standing with enough cash to fund operations into 3Q27 and a high success probability for CardiolRx in the recurrent pericarditis market.

Bears say

Cardiol Therapeutics is currently focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. However, their current success may be limited by challenging and commercially relevant questions surrounding their flagship drug, CardiolRx. While their Phase II findings provide a strong biological basis, success in their ongoing Phase III trial will depend on several key factors, including the placebo recurrence rate and the absolute treatment effect. Additionally, CardiolRx may need to demonstrate comparable anti-inflammatory effects to other available treatments in order to have a significant commercial opportunity. Overall, the outcome of their Phase III trial will be a crucial factor in determining the company's potential success in the near future.

Cardiol Therapeutics (CRDL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.